In line with the sensitivity of basal urothelial carcinoma to HDAC inhibitors, we identified the arginine–glutamic acid dipeptide repeats gene (RERE) as a leading regulon active in basal BLCA cell lines (Figure 1D, p < 0.001). This evidence concerns the gene HDAC9 and urothelial carcinoma.